03:12:36 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-02-28 Bokslutskommuniké 2022
2023-02-09 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning RLS 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-06-17 Årsstämma 2021
2021-05-27 Ordinarie utdelning RLS 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-10 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning RLS 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-19 Extra Bolagsstämma 2019
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning RLS 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-30 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning RLS 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-31 Kvartalsrapport 2018-Q1
2018-02-28 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-11-15 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-09 Ordinarie utdelning RLS 0.00 SEK
2017-06-08 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-02-20 Bokslutskommuniké 2016
2016-11-30 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2
2016-06-01 Ordinarie utdelning RLS 0.00 SEK
2016-05-31 Årsstämma 2016
2016-05-31 Kvartalsrapport 2016-Q1
2016-02-29 Bokslutskommuniké 2015
2016-01-21 Extra Bolagsstämma 2016
2015-11-30 Kvartalsrapport 2015-Q3
2015-08-31 Kvartalsrapport 2015-Q2
2015-06-12 Ordinarie utdelning RLS 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-09-12 Extra Bolagsstämma 2014
2014-08-29 Kvartalsrapport 2014-Q2
2014-06-10 Ordinarie utdelning RLS 0.00 SEK
2014-06-09 Årsstämma 2014
2014-05-23 Kvartalsrapport 2014-Q1
2014-03-05 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-09-04 Kvartalsrapport 2013-Q2
2013-05-31 Kvartalsrapport 2013-Q1
2013-05-08 Split RLS 10:1
2013-04-11 Ordinarie utdelning RLS 0.00 SEK
2013-04-10 Årsstämma 2013
2013-03-05 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-31 Kvartalsrapport 2012-Q2
2012-06-12 Ordinarie utdelning RLS 0.00 SEK
2012-06-11 Årsstämma 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
RLS Global är verksamma inom bioteknik. Bolaget utvecklar biokemiska produkter och metoder för behandling av förekommande sår hos patienter. Bolagets produkter angriper skadad vävnad via den egenutvecklade teknologin som baseras på hypoklorit. Idag bedrivs forskning och utveckling inom vävnadsbaserad teknik. Bolaget har sitt huvudkontor i Göteborg.
2022-04-04 08:55:00

Karin Fischer has given notice that she intends to resign as CEO of RLS Global AB (publ). The Board has initiated the search for a new, R&D-focused CEO and Karin Fischer will continue in her role, until a new CEO has been appointed, to ensure a smooth succession.

RLS Global ("RLS") has over the past few years, under Karin Fischer's leadership, transformed into a commercial stage wound care company. The expansion in Europe is well underway through our partnership with ConvaTec, which is responsible for the commercialization of ChloraSolv in these markets. European regulatory approval for ChloraSolv, the company's main product for debridement of hard-to-heal wounds, has been secured and the product is launched in certain European countries. As previously communicated, RLS' strategic focus is on expanding ChloraSolv into new indications and therapeutic areas, such as burns, pressure ulcers and animal care, through clinical trials generating further clinical evidence. The focus is also on expanding into new geographies through the partnership with ConvaTec and/or with other leading companies.

"We are grateful for Karin Fischer's contribution to RLS as CEO, including bringing ChloraSolv to the market and securing a leading, global commercial partner. Karin has also hired a strong management team which is important and makes us well equipped for the next stage in the company's development." says Steve Krognes, Chairman of the Board, RLS.

"It has been a privilege to lead RLS over the past few years, and together with the leadership team successfully bringing ChloraSolv to patients in need. I am personally convinced that ChloraSolv will lead to significant patient benefits in the years to come as the full potential of this product is realized," says Karin Fischer, CEO, RLS.

"We are now entering a new phase for RLS, with focus on accelerating the global expansion of ChloraSolv and realizing the full potential of our unique buffered hypoclorite platform. This means, among other things, establishing reimbursement and sales of ChloraSolv throughout Europe, and securing further regulatory approvals in new markets such as the US. It also means a broadening of the medical indications through clinical studies and investigating the potential of ChloraSolv in animal care.

To succeed in this, we intend to hire a CEO with broad regulatory and R&D expertise, as well as managing strategic partnerships and international expansion. Karin Fischer, who has been CEO of RLS since August 2018, will continue in her role and ensure a smooth leadership transition until the right successor has been appointed," concludes Steve Krognes.

TRADING PLACE AND CERTIFIED ADVISER
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se.During the period 2012-2017, the company was listed on Aktietorget.

RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contact person, 04-04-2022 08:55 CET.